Cargando…

Limited effects of azithromycin on the oropharyngeal microbiome in children with CF and early pseudomonas infection

BACKGROUND: Tobramycin inhalation solution (TIS) and chronic azithromycin (AZ) have known clinical benefits for children with CF, likely due to antimicrobial and anti-inflammatory activity. The effects of chronic AZ in combination with TIS on the airway microbiome have not been extensively investiga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wagner, Brandie D., Zemanick, Edith T., Sagel, Scott D., Robertson, Charles E., Stevens, Mark J., Mayer-Hamblett, Nicole, Retsch-Bogart, George, Ramsey, Bonnie W., Harris, J. Kirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612347/ https://www.ncbi.nlm.nih.gov/pubmed/37891457 http://dx.doi.org/10.1186/s12866-023-03073-8

Ejemplares similares

Impact of enzymatic digestion on bacterial community composition in CF airway samples
por: Williamson, Kayla M., et al.
Publicado: (2017)

Reliability of Quantitative Real-Time PCR for Bacterial Detection in Cystic Fibrosis Airway Specimens
por: Zemanick, Edith T., et al.
Publicado: (2010)

Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations
por: Zemanick, Edith T., et al.
Publicado: (2013)

Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis
por: Hoppe, Jordana E., et al.
Publicado: (2017)

Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis()
por: Hoppe, Jordana E., et al.
Publicado: (2018)

Molecular Identification of Staphylococcus aureus in Airway Samples from Children with Cystic Fibrosis
por: Johnson, Emily J., et al.
Publicado: (2016)

Clinical characteristics of people with cystic fibrosis and frequent fungal infection
por: Poore, T. Spencer, et al.
Publicado: (2021)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

On the Use of Diversity Measures in Longitudinal Sequencing Studies of Microbial Communities
por: Wagner, Brandie D., et al.
Publicado: (2018)

Divergence of bacterial communities in the lower airways of CF patients in early childhood
por: O’Connor, John B., et al.
Publicado: (2021)

Intestinal Lesions Are Associated with Altered Intestinal Microbiome and Are More Frequent in Children and Young Adults with Cystic Fibrosis and Cirrhosis
por: Flass, Thomas, et al.
Publicado: (2015)

Editorial Commentary: Pseudomonas aeruginosa Eradication: How Do We Measure Success?
por: Zemanick, Edith T., et al.
Publicado: (2015)

Airway Microbiota in Bronchoalveolar Lavage Fluid from Clinically Well Infants with Cystic Fibrosis
por: Laguna, Theresa A., et al.
Publicado: (2016)

The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network
por: Pearson, Kelsie, et al.
Publicado: (2021)

Change in circulating proteins during treatment of pulmonary exacerbation in patients with cystic fibrosis
por: Wagner, Brandie D., et al.
Publicado: (2021)

Antivirulence activity of azithromycin in Pseudomonas aeruginosa
por: Imperi, Francesco, et al.
Publicado: (2014)

Evaluation of tests to predict metallo-β-lactamase in cystic fibrosis (CF) and non-(CF) Pseudomonas
por: Perez, Leandro Reus Rodrigues, et al.
Publicado: (2014)

Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
por: Clancy, J P, et al.
Publicado: (2013)

Influence of chronic azithromycin treatment on the composition of the oropharyngeal microbial community in patients with severe asthma
por: Lopes dos Santos Santiago, Guido, et al.
Publicado: (2017)

Mechanism of azithromycin inhibition of HSL synthesis in Pseudomonas aeruginosa
por: Zeng, Jianming, et al.
Publicado: (2016)

Application of Two-Part Statistics for Comparison of Sequence Variant Counts
por: Wagner, Brandie D., et al.
Publicado: (2011)

Novel Device to Sample the Esophageal Microbiome—The Esophageal String Test
por: Fillon, Sophie A., et al.
Publicado: (2012)

Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time
por: Crull, Mathew R., et al.
Publicado: (2016)

Specific Microbiome Changes in a Mouse Model of Parenteral Nutrition Associated Liver Injury and Intestinal Inflammation
por: Harris, J. Kirk, et al.
Publicado: (2014)

Does Pseudomonas aeruginosa Colonization Affect Exercise Capacity in CF?
por: Kampouras, Asterios, et al.
Publicado: (2019)

Impact of Azithromycin on the Quorum Sensing-Controlled Proteome of Pseudomonas aeruginosa
por: Swatton, J. E., et al.
Publicado: (2016)

PA3297 Counteracts Antimicrobial Effects of Azithromycin in Pseudomonas aeruginosa
por: Tan, Hao, et al.
Publicado: (2016)

Could Azithromycin Be Part of Pseudomonas aeruginosa Acute Pneumonia Treatment?
por: Leroy, Anne-Gaëlle, et al.
Publicado: (2021)

The nasal and oropharyngeal microbiomes of healthy livestock workers
por: Kates, Ashley E., et al.
Publicado: (2019)

The Effect of Influenza Virus on the Human Oropharyngeal Microbiome
por: Ramos-Sevillano, Elisa, et al.
Publicado: (2019)

Pseudomonas aeruginosa and the Oropharyngeal Ecosystem of Tube-Fed Patients
por: Leibovitz, Arthur, et al.
Publicado: (2003)

Volatile molecules from bronchoalveolar lavage fluid can ‘rule-in’ Pseudomonas aeruginosa and ‘rule-out’ Staphylococcus aureus infections in cystic fibrosis patients
por: Nasir, Mavra, et al.
Publicado: (2018)

Mass Azithromycin Distribution and Community Microbiome: A Cluster-Randomized Trial
por: Doan, Thuy, et al.
Publicado: (2018)

Azithromycin: An Underappreciated Quinolone-Sparing Oral Treatment for Pseudomonas aeruginosa Infections
por: Ulloa, Erlinda R., et al.
Publicado: (2022)

Changes in the stool and oropharyngeal microbiome in obsessive-compulsive disorder
por: Domènech, Laura, et al.
Publicado: (2022)

Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design
por: Mayer-Hamblett, Nicole, et al.
Publicado: (2021)

Nutrient Availability as a Mechanism for Selection of Antibiotic Tolerant Pseudomonas aeruginosa within the CF Airway
por: Hoffman, Lucas R., et al.
Publicado: (2010)

Esophageal Microbiome in Eosinophilic Esophagitis
por: Harris, J. Kirk, et al.
Publicado: (2015)

In vivo imaging of the lung inflammatory response to Pseudomonas aeruginosa and its modulation by azithromycin
por: Stellari, Fabio, et al.
Publicado: (2015)

Erratum: Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qvpo49n57en8bkv863bl8m7dom